Lijuan Shao

Lijuan Shao

Auto-generated profile, based on publicly available information

Lijuan Shao

Translational Medicine Collaborative Innovation Center, The Second Clinical Medical College (Shenzhen People’s Hospital), Jinan University , Shenzhen 518020 , China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Scientific Reports
Verified
Journal Article
Open access
TWTingting Wu
Tingting Wu
YZYang Zhao
Yang Zhao
HWHao Wang
Hao Wang
YLYang Li
Yang Li
LSLijuan Shao
Lijuan Shao
Yong ZhaoYong Zhao
Yong Zhao
CD11b+ Gr1+ myeloid-derived suppressor cells (MDSCs) play critical roles in controlling the processes of tumors, infections, autoimmunity and graft rejection. Immunosuppressive drug rapamycin (RPM), targeting on the key cellular metabolism molecule mTOR, is currently used in clinics to treat patients with allo-grafts, autoimmune diseases and tumors. However, the effect of RPM on MDSCs has not been studied. RPM significantly decreases the cell number and the immunosuppressive ability on T cells of CD11b+ Ly6Chigh monocytic MDSCs (M-MDSCs) in both allo-grafts-transplanted and tumor-bearing mice respectively. Mice with a myeloid-specific deletion of mTOR have poor M-MDSCs after grafting with allo-skin tissue or a tumor. Grafting of allo-skin or tumors significantly activates glycolysis pathways in myeloid precursor cells in bone marrow, which is inhibited by RPM or mTOR deletion. 2-deoxyglucose (2-DG), an inhibitor of the glycolytic pathway, inhibits M-MDSC differentiation from precursors, while enhancing glycolysis by metformin significantly rescues the RPM-caused deficiency of M-MDSCs. Therefore, we offer evidence supporting that mTOR is an intrinsic factor essential for the differentiation and immunosuppressive function of M-MDSCs and that these metabolism-relevant medicines may impact MDSCs-mediated immunosuppression or immune tolerance induction, which is of considerable clinical importance in treating graft rejection, autoimmune diseases and cancers.

2 June 2015 in Cancer Biomarkers
Verified
Journal Article
Closed access
TTTian Tian
Tian Tian
XGXiaobin Gu
Xiaobin Gu
BZBo Zhang
Bo Zhang
YLYang Liu
Yang Liu
CYChao Yuan
Chao Yuan
KFKexing Fan
Kexing Fan
High expression of CD14(+)HLA-DR-/low myeloid-derived suppressor cells (MDSCs) is correlated with immunosuppressive activity in various cancers, however, no studies have shown a correlation of these immunosuppressive cells with clinical outcomes in small-cell lung cancer (SCLC) patients. The purpose of the study was to investigate the number, frequency and clinical significance of CD14(+)HLA-DR-/low MDSCs in SCLC patients. The peripheral blood of 42 patients with SCLC and 37 healthy controls was analyzed by using flow cytometry. The relationships between the number and frequency of MDSCs, clinicopathological features and overall survival(OS) were analyzed. The prognostic value of MDSCs was tested by using univariate and multivariate analysis. Our results demonstrated that number and frequency of peripheral CD14(+)HLA-DR-/low MDSCs were significantly increased in SCLC patients than in controls (p< 0.0001 and p< 0.0001, respectively). The frequency of MDSCs correlated with tumor stage (p= 0.02), serum LDH levels (p= 0.001) and with the poorer OS (log-rank test, p= 0.017). Univariate and multivariate analyses suggested that frequency of CD14(+)HLA-DR-/low MDSCs as an independent biomarker for poor prognosis in SCLC patients during follow-up. Our study provides the first evidence that the frequency of CD14(+)HLA-DR-/low MDSCs negatively correlates with clinical outcomes in SCLC patients. The frequency of CD14(+)HLA-DR-/low MDSCs could be considered as a poor prognostic predictor in SCLC and the elimination of MDSCs during medical interventions may improve the prognosis of SCLC patients.

23 July 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
HCHui Chen
Hui Chen
LZLianjun Zhang
Lianjun Zhang
HZHongbing Zhang
Hongbing Zhang
YXYi Xiao
Yi Xiao
LSLijuan Shao
Lijuan Shao
Yong ZhaoYong Zhao
Yong Zhao
Thymic‐derived CD4 + CD25 + Foxp3 + natural regulatory T (nT reg ) cells are essential for the maintenance of peripheral immune tolerance. Signaling pathways that drive immature thymic progenitors to differentiate into CD4 + CD25 + Foxp3 + nT reg cells need to be elucidated. The precise role of the TSC1/2 complex, a critical negative regulator of mammalian target of rapamycin (mTOR), in thymic CD4 + CD25 + Foxp3 + nT reg ‐cell develop ment remains elusive. In the present study, we found that the percentage and cell number of thymic CD4 + CD25 + Foxp3 + nT reg cells were significantly increased in T‐cell‐specific TSC1‐knockout (TSC1KO) mice. Nevertheless, the levels of CD4 + CD25 + Foxp3 – nT reg precursors in TSC1KO thymus were indistinguishable from those in wild‐type mice. TSC1KO CD4 + CD25 + Foxp3 + nT reg cells showed normal cell death but enhanced proliferative response to IL‐2 in a STAT5‐dependent manner. Rapamycin (Rapa) treatment failed to rescue but rather increased the frequency of CD4 + CD25 + Foxp3 + nT reg cells in TSC1KO and RictorKO mice. The percentage and cell number of thymic CD4 + CD25 + Foxp3 + nT reg cells were significantly increased in T‐cell‐specific RictorKO mice but not in PtenKO mice. Collectively, our studies suggest that TSC1 plays an important role in regulating thymic CD4 + CD25 + Foxp3 + nT reg ‐cell development via a Rapa‐resistant and mTORC2‐dependent signaling pathway.—Chen, H, Zhang, L., Zhang, H., Xiao, Y., Shao, L., Li, H., Yin, H., Wang, R., Liu, G., Corley, D., Yang, Z., Zhao, Y., Disruption of TSC1/2 signaling complex reveals a checkpoint governing thymic CD4+CD25+Foxp3+ regulatory T‐cell development in mice. FASEB J. 27, 3979–3990 (2013). www.fasebj.org

1 December 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
LSLijuan Shao
Lijuan Shao
BZBo Zhang
Bo Zhang
LWLingxiong Wang
Lingxiong Wang
LWLiangliang Wu
Liangliang Wu
QKQuancheng Kan
Quancheng Kan
KFKexing Fan
Kexing Fan

14 June 2021 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
HLHaitao Luo
Haitao Luo
YZYuan-Yuan Zheng
Yuan-Yuan Zheng
JTJun Tang
Jun Tang
LSLi-Juan Shao
Li-Juan Shao
YMYi-Heng Mao
Yi-Heng Mao
FLFu-Rong Li
Fu-Rong Li
Lung adenocarcinoma is heterogeneous and hierarchically organized, with a subpopulation of stem-like cells (CSCs) that reside at the apex of the hierarchy, in which exosomes act as important mediators by transporting specific molecules among different cell populations. Although there have been numerous studies on tumor exosomes, the constituents and functional properties of CSC-derived exosomes are still poorly characterized. Here we present a detail transcriptome and proteome atlas of the exosomes released by human lung adenocarcinoma stem-like cells (LSLCs). The transcriptome analysis indicates the specific patterns of exosomal constituents, including the fragmentation of transcripts and the low-level presence of circular RNAs, and identifies multiple exosomal-enriched mRNAs and lncRNAs. Integrative analysis of transcriptome and proteome data reveals the diverse functions of exosomal-enriched RNAs and proteins, many of which are associated with tumorigenesis. Importantly, several LSLC markers we identified are highly expressed in LSLC-derived exosomes and associate with poor survival, which may serve as promising liquid biopsy biomarkers for lung adenocarcinoma diagnosis. Our study provides a resource for the future elucidation of the functions of tumor-derived exosomes and their regulatory mechanisms in mediating lung cancer development.

15 June 2021 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
LSLijuan Shao
Lijuan Shao
QHQian He
Qian He
JWJingbo Wang
Jingbo Wang
FHFei He
Fei He
SLShengcheng Lin
Shengcheng Lin
FLFu-Rong Li
Fu-Rong Li
Tumor-infiltrating T cells are highly expressive of inhibitory receptor/immune checkpoint molecules that bind to ligand expressed by tumor cells and antigen-presenting cells, and eventually lead to T cell dysfunction. It is a hot topic to restore T cell function by targeting immune checkpoint. In recent years, immunotherapy of blocking immune checkpoint and its receptor, such as PD-L1/PD-1 targeted therapy, has made effective progress, which brings hope for patients with advanced malignant tumor. However, only a few patients benefit from directly targeting these checkpoints or their receptors by small compounds or antibodies. Since the complexity of the regulation of immune checkpoints in tumor cells, further research is needed to identify the novel endogenous regulators of immune checkpoints which can help for developing effective drug target to improve the effect of immunotherapy. Here, we verified that microRNA-326 (miR-326) repressed the gene expression of immune checkpoint molecules PD-L1 and B7-H3 in lung adenocarcinoma (LUAD). We detected that the expression of miR-326 in LUAD tissue was negatively correlated with PD-L1/B7-H3. The repression of PD-L1 and B7-H3 expression through miR-326 overexpression leads to the modification the cytokine profile of CD8+ T cells and decreased migration capability of tumor cells. Meanwhile, the downregulation of miR-326 promoted tumor cell migration. Moreover, blocking PD-L1 and B7-H3 attenuated the tumor-promoting effect induced by miR-326 inhibitor. In tumor-bearing mice, the infiltration of CD8+ T cells was significantly increased and the expression of TNF-α, and IFN-γ was significantly enhanced which contributed to tumor progression after miR-326 overexpression. Collectively, miR-326 restrained tumor progression by downregulating PD-L1 and B7-H3 expression and increasing T cell cytotoxic function in LUAD. Our findings revealed a novel perspective on the complex regulation of immune checkpoint molecules. A new strategy of using miR-326 in tumor immunotherapy is proposed.